Hold Brilinta (Ticagrelor) for 5 Days Before Spinal Procedures
For spinal procedures including spinal puncture or spinal surgery, hold ticagrelor (Brilinta) for 5 days (120 hours) before the procedure. This recommendation applies specifically to high-bleeding-risk procedures like spinal/neuraxial interventions where the consequences of bleeding (spinal hematoma with potential paralysis) are catastrophic.
Evidence-Based Rationale
The FDA label for Brilinta explicitly states: "When possible, interrupt therapy with BRILINTA for five days prior to surgery that has a major risk of bleeding" 1. Spinal procedures unequivocally fall into this high-bleeding-risk category.
The 2022 American College of Chest Physicians guideline provides a general recommendation of 3-5 days for elective non-cardiac surgery 2, but critically notes this "may be modified on a case-by-case basis, depending on individual patient circumstances; for example, surgery-related bleeding risk" 2. Given that spinal procedures carry extreme bleeding consequences (epidural/spinal hematoma can cause permanent paralysis), the longer 5-day interval is appropriate.
Why 5 Days for Spinal Procedures?
The French perioperative guidelines 3 provide important mechanistic insight: while most patients achieve adequate platelet recovery after 72-120 hours of ticagrelor discontinuation, approximately 25% of patients still have inadequate platelet function recovery at 72 hours 3. This persistent platelet inhibition correlates with increased perioperative bleeding risk. The guidelines therefore recommend 5 days of discontinuation for invasive procedures to account for this interindividual variability 3.
For spinal/neuraxial procedures specifically, even a small risk of inadequate hemostasis is unacceptable given the devastating consequences of spinal hematoma. One case report 4 describes the complexity of managing epidural catheter removal in a patient on ticagrelor, requiring 5 days after the last dose and intensive multidisciplinary monitoring.
Practical Algorithm
Preoperative holding period:
- Stop ticagrelor 5 days (120 hours) before scheduled spinal procedure
- Verify last dose timing with patient
- In patients with renal impairment, consider extending the interval as drug clearance may be prolonged
Postoperative resumption:
- Resume ticagrelor as soon as hemostasis is achieved per FDA guidance 1
- Typically this means 24-48 hours post-procedure for most patients
- For patients at very high thrombotic risk (recent stent, acute coronary syndrome), consider earlier resumption once surgical hemostasis is secure
- Never resume while epidural catheter is in place - remove catheter first, then wait appropriate interval before restarting
Critical Caveats
Do not confuse this with aspirin management: The ACCP guideline mentions ≤7 days for aspirin in high-bleeding-risk surgery 2, but ticagrelor is a far more potent antiplatelet agent requiring the full 5-day washout.
Coordinate with cardiology: Stopping ticagrelor increases thrombotic risk in patients with coronary artery disease, recent stents, or acute coronary syndromes 1. The decision to hold must balance bleeding versus thrombotic risk, but for elective spinal procedures, the 5-day hold is standard. For urgent/emergent spinal procedures in patients on ticagrelor, this becomes a complex risk-benefit discussion requiring multidisciplinary input 4.
Epidural catheter considerations: If an epidural catheter is in place and ticagrelor must be started (e.g., urgent cardiac indication), catheter removal timing becomes extremely complex and requires case-by-case assessment with heightened neurologic monitoring 4.